SCHEMBL420092

SCHEMBL420092

CCC1C2CCC(N(C)C(=O)C(=O)N(C)C)(CO2)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n21

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.49
KCNH2 Q12809 1/20 0.42
KCNE1 P15382 1/20 0.38
CCR1 P32246 1/20 0.38
KCNQ1 P51787 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 2/20 0.33
TSHR P16473 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ERCC1 P07992 1/20 0.33
FEN1 P39748 1/20 0.33
ERCC4 Q92889 1/20 0.33
CALCA P06881 1/20 0.33
LIPG Q9Y5X9 1/20 0.32
ALDH1A1 P00352 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL419105 0.93 KCNH2 (0.43) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL416731 0.91 CYP2C9 (0.52) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL10143691 0.89 KCNH2 (0.42) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL10143836 0.86 CYP2C9 (0.47) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL418531 0.85 CYP2C9 (0.46) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL10143686 0.85 CYP2C9 (0.55) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL13255645 0.84 CYP2C9 (0.52) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL10143835 0.83 KCNH2 (0.42) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL10143669 0.83 CYP2C9 (0.54) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL419104 0.83 CYP2C9 (0.44) CYP2C9KCNH2KCNE1CCR1KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS VENKATRAMAN SHANKAR (US) 2012-01-26 US claimed
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS VENKATRAMAN SHANKAR (US) 2012-01-26 US disclosed
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS VENKATRAMAN SHANKAR (US) 2012-01-26 US disclosed
WO-2010088167-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS CCND3, CDK3, CDK2 CYP2C9 1960/4885KCNH2 2502/4885KCNE1 2089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.